-transparent.png){kind=logo}
In a previous report we showed that oestriol succinate administered to postmenopausal women caused fewer changes in haemostatic function over a four-month period than ethinyloestradiol. Potential longer-term effects were studied in postmenopausal women treated for osteoporosis with oestriol succinate for up to 12 months. Over this period there was no significant change in concentration of plasma coagulation factors, an increase in plasminogen concentration and euglobulin lysis activity, and an inconsistent increase in platelet sensitivity to aggregation induced by ADP and collagen. The relative lack of effect of oestriol succinate on coagulation function is encouraging with regard to the future incidence of thromboembolic complications of therapy.
J L Toy, and
J A Davies, and
G P McNicol
April 1976,
Thrombosis and haemostasis,
J L Toy, and
J A Davies, and
G P McNicol
January 1977,
Annales chirurgiae et gynaecologiae,
J L Toy, and
J A Davies, and
G P McNicol
January 1976,
Annales chirurgiae et gynaecologiae,
J L Toy, and
J A Davies, and
G P McNicol
April 1973,
Arzneimittel-Forschung,
J L Toy, and
J A Davies, and
G P McNicol
June 1979,
Maturitas,
J L Toy, and
J A Davies, and
G P McNicol
January 1977,
Annales chirurgiae et gynaecologiae,
J L Toy, and
J A Davies, and
G P McNicol
November 1996,
Bone,
J L Toy, and
J A Davies, and
G P McNicol
January 2008,
Thrombosis research,
J L Toy, and
J A Davies, and
G P McNicol
October 2001,
Maturitas,
J L Toy, and
J A Davies, and
G P McNicol
February 2001,
The Journal of clinical endocrinology and metabolism,
